ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters
My wife, a fellow OSU patient, Wally, and my treatment team from OSU at the CARE CLL HERO Gala
I am way too tired to write about all the incredible CLL news at ASH (some are say this shouldn’t be call ASH 2018 but CLL 2018), but let me just say the abstracts and oral presentations on targeted therapies versus chemo and the new targeted combinations are amazing and should change how all CLL is treated.
Several great interviews recorded today.
Yesterday I won the CARE DIFFERENTLY award from Verastem Oncology.
Today I was recipient of the CURE 2018 CLL HERO award.
I have to pinch myself sometimes to see the if am really awake, living this dream.
Related posts
